Biogen Idec Inc (BIIB) 345.84 $BIIB
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Biogen's buy rating reaffirmed
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
The biotech's overweight or buy rating was reaffirmed by Morgan Stanley on the FDA's approval of Biogen's (BIIB) new Plegridy drug for people with multiple sclerosis on Fri. The new treatment is a long-lasting form of the company's Avonex drug and...
Why Biogen Idec (BIIB) Stock Is Gaining Today
at The Street - Mon Aug 18, 10:44AM CDT
Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.
Isis Pharmaceuticals earns USD2m for advancement of ISIS-SMN Rx in children with SMA from Biogen Idec
M2 - Mon Aug 18, 7:20AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the receipt of a USD2m milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).
Biogen Idec awarded US FDA approval for PLEGRIDY for treating multiple sclerosis
M2 - Mon Aug 18, 5:33AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for treating people with relapsing forms of multiple sclerosis (RMS) with the new subcutaneous injectable therapy, PLEGRIDY.
FDA approves Biogen's MS drug Plegridy
AP - Fri Aug 15, 6:27PM CDT
CAMBRIDGE, Mass. (AP) — Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.
Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Business Wire - Fri Aug 15, 5:44PM CDT
--a^' Only Pegylated Interferon in MS, Dosed Once Every Two Weeks -
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.62% Rise
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Momo Momentum Stock Is Biogen Idec (BIIB)
at The Street - Fri Aug 15, 8:49AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
PR Newswire - Fri Aug 15, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).
Global Biological Drugs Market 2014 - 2020 - Industry Analysis for the $161.056 Million Industry
M2 - Fri Aug 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjz57l/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix. Globally, the biological drugs market is witnessing a significant growth due to increasing prevalence of various chronic diseases, as the demand for biological drugs is increasing with the rise in the global geriatric population. The biological drugs are used in the treatment and prevention of various diseases, such as blood related diseases, cancer, auto-immune diseases and other medical disorders. Additionally, various government associations are promoting the usage of biological drugs. Moreover, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein. In monoclonal antibody (mAb), Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/hj...ical_drugs
Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:29PM CDT
Perrigo (PRGO) reported higher than expected earnings and revenues in the fourth quarter.
Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks
at The Street - Thu Aug 14, 11:34AM CDT
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.
Perrigo Q4 Beats Estimates, But Guidance Misses
at Investor's Business Daily - Thu Aug 14, 10:02AM CDT
Drugmaker Perrigo (PRGO) beat Wall Street's Q4 expectations Thursday morning, sending the stock up 6% on the stock market today even though its 2015 guidance missed estimates. Sales for the quarter ended June 28 rose 18% over the year-earlier quarter...
Stock Market News for August 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:10AM CDT
Benchmarks ended in the green as gains in biotech stocks offset discouraging retail sales numbers
Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - Thu Aug 14, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (
- Europe (19) - France (1) - Germany ( - The United Kingdom (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (24) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/bq...th_factors
Rush University Medical Center Sells AMPYRA(R) Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Business Wire - Tue Aug 12, 7:01AM CDT
DRI Capital Inc. (DRI) and Rush University Medical Center (Rush) announced today that Drug Royalty III, a private equity fund managed by DRI has purchased Rush's royalties relating to worldwide sales of Ampyra(R) for approximately $42 million. Ampyra(R) (dalfampridine) extended release tablets, 10 mg, twice daily, were approved for use in the US in January 2010, and received conditional approval in Europe, where it is known as Fampyra(R), in July 2011. Ampyra is marketed by Acorda Therapeutics, Inc. (Acorda), within the United States, and by Acorda's licensee, Biogen IDEC, internationally.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.14%
Comtex SmarTrend(R) - Mon Aug 11, 3:57PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.07 to a high of $327.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $319.32 on volume of 981,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Biogen's buy rating reaffirmed
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
The biotech's overweight or buy rating was reaffirmed by Morgan Stanley on the FDA's approval of Biogen's (BIIB) new Plegridy drug for people with multiple sclerosis on Fri. The new treatment is a long-lasting form of the company's Avonex drug and...
Why Biogen Idec (BIIB) Stock Is Gaining Today
at The Street - Mon Aug 18, 10:44AM CDT
Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.
Isis Pharmaceuticals earns USD2m for advancement of ISIS-SMN Rx in children with SMA from Biogen Idec
M2 - Mon Aug 18, 7:20AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the receipt of a USD2m milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).
Biogen Idec awarded US FDA approval for PLEGRIDY for treating multiple sclerosis
M2 - Mon Aug 18, 5:33AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for treating people with relapsing forms of multiple sclerosis (RMS) with the new subcutaneous injectable therapy, PLEGRIDY.
FDA approves Biogen's MS drug Plegridy
AP - Fri Aug 15, 6:27PM CDT
CAMBRIDGE, Mass. (AP) — Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.
Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Business Wire - Fri Aug 15, 5:44PM CDT
--a^' Only Pegylated Interferon in MS, Dosed Once Every Two Weeks -
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.62% Rise
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Momo Momentum Stock Is Biogen Idec (BIIB)
at The Street - Fri Aug 15, 8:49AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
PR Newswire - Fri Aug 15, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).
Global Biological Drugs Market 2014 - 2020 - Industry Analysis for the $161.056 Million Industry
M2 - Fri Aug 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjz57l/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix. Globally, the biological drugs market is witnessing a significant growth due to increasing prevalence of various chronic diseases, as the demand for biological drugs is increasing with the rise in the global geriatric population. The biological drugs are used in the treatment and prevention of various diseases, such as blood related diseases, cancer, auto-immune diseases and other medical disorders. Additionally, various government associations are promoting the usage of biological drugs. Moreover, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein. In monoclonal antibody (mAb), Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/hj...ical_drugs
Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:29PM CDT
Perrigo (PRGO) reported higher than expected earnings and revenues in the fourth quarter.
Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks
at The Street - Thu Aug 14, 11:34AM CDT
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.
Perrigo Q4 Beats Estimates, But Guidance Misses
at Investor's Business Daily - Thu Aug 14, 10:02AM CDT
Drugmaker Perrigo (PRGO) beat Wall Street's Q4 expectations Thursday morning, sending the stock up 6% on the stock market today even though its 2015 guidance missed estimates. Sales for the quarter ended June 28 rose 18% over the year-earlier quarter...
Stock Market News for August 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:10AM CDT
Benchmarks ended in the green as gains in biotech stocks offset discouraging retail sales numbers
Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - Thu Aug 14, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (
- Europe (19) - France (1) - Germany ( - The United Kingdom (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (24) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/bq...th_factors Rush University Medical Center Sells AMPYRA(R) Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Business Wire - Tue Aug 12, 7:01AM CDT
DRI Capital Inc. (DRI) and Rush University Medical Center (Rush) announced today that Drug Royalty III, a private equity fund managed by DRI has purchased Rush's royalties relating to worldwide sales of Ampyra(R) for approximately $42 million. Ampyra(R) (dalfampridine) extended release tablets, 10 mg, twice daily, were approved for use in the US in January 2010, and received conditional approval in Europe, where it is known as Fampyra(R), in July 2011. Ampyra is marketed by Acorda Therapeutics, Inc. (Acorda), within the United States, and by Acorda's licensee, Biogen IDEC, internationally.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.14%
Comtex SmarTrend(R) - Mon Aug 11, 3:57PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.07 to a high of $327.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $319.32 on volume of 981,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
